Shares of USA Rare Earth (NASDAQ: USAR) recovered Wednesday following a sharp sell-off, buoyed by an analyst's upgraded price target and reinforced by a recent $3.5 billion capital infusion from public and private sources.
Tesla's latest earnings call, emphasizing a strategic shift towards autonomous vehicles and robotics, has drawn a spectrum of reactions from prominent investors. While some see it as a necessary evolution, others warn of significant costs and transitional risks, creating a clear divide in analyst sentiment.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Wall Street analysts have updated their price target for Amcor (NYSE: AMCR), prompting a fresh look at the investment case for the global packaging leader. The revision reflects evolving views on the company's strategic positioning and market dynamics.
Citizens and Mizuho reaffirm positive ratings for Zscaler, highlighting its formidable competitive advantages rooted in complex implementation and high switching costs that lock in enterprise clients.
As industry analysts warn of a critical NAND wafer shortage in 2026-2027, SanDisk's stock soars. Jim Cramer highlights the memory maker's positioning, with Mizuho and Benchmark raising price targets significantly on expectations of a 330% price spike.
Advanced Micro Devices (AMD) shares have soared over 115% in the past year, driven by its strategic positioning in the artificial intelligence sector. Recent analyst upgrades highlight optimism around its partnership with OpenAI and broader AI chip demand.
Despite reporting earnings that edged past expectations, Houlihan Lokey's shares fell 12% post-earnings. Analysts' long-term forecasts remain largely unchanged, signaling a 'steady-as-she-goes' assessment of the investment bank's prospects.
The educational streaming service CuriosityStream Inc. (NASDAQ: CURI) is drawing strong analyst support following robust Q3 2025 results, with a consensus 'Strong Buy' rating and a $6 price target highlighting significant growth potential from its current trading level.
Shares of Lionsgate Studios Corp. receive a vote of confidence from Seaport Research, which raised its price target following strong box office results. The move underscores broader analyst support for the newly independent content company's library monetization and strategic use of AI.
Wall Street analysts have issued a dramatic upgrade to revenue projections for Americas Gold and Silver Corp., forecasting a surge to $383 million by 2026 and signaling accelerated growth far beyond industry peers.
A revised price target for Rithm Capital (NYSE: RITM) has prompted a fresh look at the mortgage REIT's prospects, with analysts weighing its strategic shifts against a complex macroeconomic backdrop.
After years of losses, London-listed Buccaneer Energy (LON:BUCE) is projected by analysts to turn its first profit in 2026, marking a potential turning point for the US-focused hydrocarbon explorer.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
London-listed mineral sands explorer Capital Metals (LON: CMET) is projected to reach breakeven within two years, with analysts forecasting a first profit in 2028. The debt-free company's path hinges on achieving a steep annual growth rate amid its investment phase in UK and Sri Lankan projects.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Bank of America leads a wave of analyst upgrades for DigitalOcean, citing the viral success of its AI agent 'Clawdbot' and the company's strategic positioning in the burgeoning agentic AI market for developers.
Shares of gaming and hospitality REIT VICI Properties have faced recent headwinds, trading near $28 and presenting a significant discount to analyst targets. We examine whether the current valuation gap signals a buying opportunity or reflects deeper sectoral risks.
